[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
June 27, 2012

Toward a Safer Cure for Low-Risk Hodgkin Lymphoma in Children

Author Affiliations

Author Affiliations: University of Alabama at Birmingham, Birmingham, Alabama.

JAMA. 2012;307(24):2639-2641. doi:10.1001/jama.2012.6975

Currently children and adolescents diagnosed with Hodgkin lymphoma have 5-year overall survival rates greater than 90%.1,2 Therapeutic approaches to Hodgkin lymphoma have evolved, from high-dose extended-field radiation to dose-intensive combination chemotherapy regimens (which relied heavily on alkylating agent exposure), to the current standard of care for all stages of disease in children using multiagent chemotherapy combined with low-dose involved field radiation therapy (IFRT).1 This evolution has been driven by recognition that these curative regimens have been accompanied by significant late treatment–related complications, including secondary malignancies, cardiovascular disease, pulmonary fibrosis, thyroid dysfunction, and gonadal toxicity.24 These late effects significantly influence the quality of life for survivors of Hodgkin lymphoma.

First Page Preview View Large
First page PDF preview
First page PDF preview
×